-
My Account
My Account
BSE Live
May 12, 10:35Prev. Close
837.70
Open Price
845.00
Bid Price (Qty.)
819.40 (13)
Offer Price (Qty.)
820.25 (51)
NSE Live
May 12, 10:35Prev. Close
837.75
Open Price
840.90
Bid Price (Qty.)
819.50 (99)
Offer Price (Qty.)
819.75 (90)
| Nine Months Results of Strides Pharma Science (in Rs. Cr.) | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
| Net Sales/Income from operations | 1,223.97 | 1,232.41 | 1,102.88 | 1,026.38 | 1,522.48 | |
| Other Operating Income | -- | -- | -- | -- | 88.59 | |
| Total Income From Operations | 1,223.97 | 1,232.41 | 1,102.88 | 1,026.38 | 1,611.07 | |
| EXPENDITURE | ||||||
| Consumption of Raw Materials | 669.08 | 654.08 | 674.88 | 566.95 | 708.59 | |
| Purchase of Traded Goods | 48.12 | 26.51 | 16.45 | 34.15 | 84.78 | |
| Increase/Decrease in Stocks | -49.26 | 4.11 | -34.63 | 29.41 | -22.98 | |
| Power & Fuel | -- | -- | -- | -- | -- | |
| Employees Cost | 199.09 | 158.38 | 174.32 | 183.59 | 299.45 | |
| Depreciation | 74.62 | 68.48 | 61.49 | 60.44 | 92.95 | |
| Excise Duty | -- | -- | -- | -- | -- | |
| Admin. And Selling Expenses | -- | -- | -- | -- | -- | |
| R & D Expenses | -- | -- | -- | -- | -- | |
| Provisions And Contingencies | -- | -- | -- | -- | -- | |
| Exp. Capitalised | -- | -- | -- | -- | -- | |
| Other Expenses | 257.64 | 241.27 | 210.65 | 201.64 | 345.77 | |
| P/L Before Other Inc. , Int., Excpt. Items & Tax | 24.68 | 79.58 | -0.28 | -49.80 | 102.51 | |
| Other Income | 65.69 | 72.90 | 58.20 | 139.36 | 118.86 | |
| P/L Before Int., Excpt. Items & Tax | 90.37 | 152.48 | 57.92 | 89.56 | 221.37 | |
| Interest | 47.43 | 48.39 | 37.78 | 70.53 | 85.76 | |
| P/L Before Exceptional Items & Tax | 42.94 | 104.09 | 20.14 | 19.03 | 135.61 | |
| Exceptional Items | -- | -- | -2.01 | 22.43 | -92.57 | |
| P/L Before Tax | 42.94 | 104.09 | 18.13 | 41.46 | 43.04 | |
| Tax | 12.78 | 18.76 | 2.54 | -24.26 | 9.66 | |
| P/L After Tax from Ordinary Activities | 30.17 | 85.33 | 15.59 | 65.72 | 33.38 | |
| Prior Year Adjustments | -- | -- | -- | -- | -- | |
| Extra Ordinary Items | -- | -- | -4.04 | 60.02 | -- | |
| Net Profit/(Loss) For the Period | 30.17 | 85.33 | 11.55 | 125.74 | 33.38 | |
| Equity Share Capital | 89.63 | 89.55 | 89.55 | 89.50 | 89.37 | |
| Reserves Excluding Revaluation Reserves | -- | -- | -- | -- | -- | |
| Equity Dividend Rate (%) | -- | -- | -- | -- | -- | |
| EPS Before Extra Ordinary | ||||||
| Basic EPS | 3.37 | 9.53 | 1.29 | 7.35 | 3.74 | |
| Diluted EPS | 3.36 | 9.53 | 1.29 | 7.34 | 3.73 | |
| EPS After Extra Ordinary | ||||||
| Basic EPS. | 3.37 | 9.53 | 1.29 | 7.35 | 3.74 | |
| Diluted EPS. | 3.36 | 9.53 | 1.29 | 7.34 | 3.73 | |
| Public Share Holding | ||||||
| No Of Shares (Crores) | -- | -- | -- | -- | -- | |
| Share Holding (%) | -- | -- | -- | -- | -- | |
| Promoters and Promoter Group Shareholding | ||||||
| a) Pledged/Encumbered | ||||||
| - Number of shares (Crores) | -- | -- | -- | -- | -- | |
| - Per. of shares (as a % of the total sh. of prom. and promoter group) | -- | -- | -- | -- | -- | |
| - Per. of shares (as a % of the total Share Cap. of the company) | -- | -- | -- | -- | -- | |
| b) Non-encumbered | ||||||
| - Number of shares (Crores) | -- | -- | -- | -- | -- | |
| - Per. of shares (as a % of the total sh. of prom. and promoter group) | -- | -- | -- | -- | -- | |
| - Per. of shares (as a % of the total Share Cap. of the company) | -- | -- | -- | -- | -- |
05.02.2021
Strides Pharma Consolidated December 2020 Net Sales at Rs 832.02 crore, up 13.6% Y-o-Y
05.02.2021
Strides Pharma Standalone December 2020 Net Sales at Rs 421.09 crore, up 15.53% Y-o-Y
04.02.2021
Strides Pharma Standalone December 2020 Net Sales at Rs 421.09 crore, up 15.53% Y-o-Y
04.02.2021
Strides Pharma Consolidated December 2020 Net Sales at Rs 832.02 crore, up 13.6% Y-o-Y
12.04.2021
Strides Pharma Science Q4 PAT may dip 488.7% YoY to Rs. 72.3 cr: Sharekhan
12.04.2018
Pharma Q4 earnings preview: Tough quarter; US pricing pressure, domestic sales recovery hold key
18.01.2018
Pharma Q3 earnings preview - cos brace for challenging quarter, US and India sales hold key
17.08.2016
